GlobalData on MSN11h
GLP-1RA developer Metsera targets $289m IPOMetsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.
News Medical on MSN13h
GLP-1RA initiation linked to new thyroid cancer diagnosesResearchers investigate the risk of incident thyroid cancer among patients treated with glucagon-like peptide-1 receptor ...
An observational analysis has found that the drugs may lower the risk of substance abuse and cognitive issues. But the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback